Clinical trial
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone…
NCT00391690 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00391690 |
|---|---|
| Title | Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer |
| Official title | Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Zoledronic acid |
| Enrollment | 99 |
| Start date | Feb 1, 2006 |
| Primary completion | Dec 1, 2010 |
| First posted | Oct 24, 2006 |
| Last update posted | Nov 18, 2016 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: